Pegtibatinase is a recombinant enzyme commercialized by Travere Therapeutics, with a leading Phase III program in Homocystinuria. According to Globaldata, it is involved in 3 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Pegtibatinase’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Pegtibatinase is expected to reach an annual total of $81 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Pegtibatinase Overview
Pegtibatinase (OT-58) is under development for the treatment of homocystinuria. It is administrated through subcutaneous route as a solution. The drug candidate is an enzyme replacement therapy (ERT). It is a pegylated version of truncated recombinant human cystathionine beta-synthase (CBS) enzyme.
Travere Therapeutics Overview
Travere Therapeutics, formerly Retrophin, is a biopharmaceutical company that discovers, develops, and commercializes drugs for the treatment of rare diseases. The company’s products include thiola, chenodal, and cholbam. It develops drugs for therapies for people living with liver, rare kidney and metabolic diseases. Travere Therapeutics‘ marketed product Filspari (sparsentan), is developed to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. Its pipeline products include sparsentan which is being developed for the treatment of focal segmental glomerulosclerosis and Pegtibatinase (TVT-058) being developed for the treatment of classical homocystinuria (HCU). The company markets its products through its distribution partners. It works in partnership with academia and independent researchers to support the development of novel solutions. Travere Therapeutics is headquartered in San Diego, California, the US.
The company reported revenues of (US Dollars) US$145.2 million for the fiscal year ended December 2023 (FY2023), an increase of 32.7% over FY2022. The operating loss of the company was US$388.1 million in FY2023, compared to an operating loss of US$327.4 million in FY2022. The net loss of the company was US$111.4 million in FY2023, compared to a net loss of US$278.5 million in FY2022.
The company reported revenues of US$54.1 million for the second quarter ended June 2024, an increase of 30.8% over the previous quarter.
For a complete picture of Pegtibatinase’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
